PL2648726T3 - Policykliczny antagonista lpa1 i jego zastosowania - Google Patents
Policykliczny antagonista lpa1 i jego zastosowaniaInfo
- Publication number
- PL2648726T3 PL2648726T3 PL11805292T PL11805292T PL2648726T3 PL 2648726 T3 PL2648726 T3 PL 2648726T3 PL 11805292 T PL11805292 T PL 11805292T PL 11805292 T PL11805292 T PL 11805292T PL 2648726 T3 PL2648726 T3 PL 2648726T3
- Authority
- PL
- Poland
- Prior art keywords
- policyclicic
- application
- lpa1 antagonist
- lpa1
- antagonist
- Prior art date
Links
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 title 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/14—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42059910P | 2010-12-07 | 2010-12-07 | |
| EP11805292.7A EP2648726B1 (en) | 2010-12-07 | 2011-12-07 | Polycyclic lpa1 antagonist and uses thereof |
| PCT/US2011/063817 WO2012078805A1 (en) | 2010-12-07 | 2011-12-07 | Polycyclic lpa1 antagonist and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2648726T3 true PL2648726T3 (pl) | 2018-10-31 |
Family
ID=45446189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11805292T PL2648726T3 (pl) | 2010-12-07 | 2011-12-07 | Policykliczny antagonista lpa1 i jego zastosowania |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9556133B2 (pl) |
| EP (2) | EP3360552A1 (pl) |
| JP (1) | JP6030567B2 (pl) |
| KR (1) | KR101875246B1 (pl) |
| CN (2) | CN107721940A (pl) |
| AU (2) | AU2011338417B2 (pl) |
| BR (1) | BR112013013950A2 (pl) |
| CA (1) | CA2820884A1 (pl) |
| CY (1) | CY1120342T1 (pl) |
| DK (1) | DK2648726T3 (pl) |
| EA (1) | EA024967B1 (pl) |
| ES (1) | ES2674174T3 (pl) |
| HR (1) | HRP20180970T1 (pl) |
| HU (1) | HUE040397T2 (pl) |
| IL (1) | IL226698B (pl) |
| LT (1) | LT2648726T (pl) |
| MX (1) | MX347544B (pl) |
| NO (1) | NO2648726T3 (pl) |
| PL (1) | PL2648726T3 (pl) |
| PT (1) | PT2648726T (pl) |
| RS (1) | RS57377B1 (pl) |
| SG (1) | SG191041A1 (pl) |
| SI (1) | SI2648726T1 (pl) |
| SM (1) | SMT201800320T1 (pl) |
| TR (1) | TR201809293T4 (pl) |
| WO (1) | WO2012078805A1 (pl) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112013014019A2 (pt) | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
| CN104066729A (zh) | 2011-08-15 | 2014-09-24 | 英特穆恩公司 | 溶血磷脂酸受体拮抗剂 |
| RU2756506C2 (ru) | 2012-12-28 | 2021-10-01 | Убе Индастриз, Лтд. | Галогензамещенное гетероциклическое соединение |
| TW201437200A (zh) * | 2013-01-15 | 2014-10-01 | Intermune Inc | 溶血磷脂酸受體拮抗劑 |
| SG11201507459YA (en) | 2013-03-15 | 2015-10-29 | Epigen Biosciences Inc | Heterocyclic compounds useful in the treatment of disease |
| DK3003038T3 (da) | 2013-06-07 | 2019-11-11 | Scripps Research Inst | 2h-1,2,3-triazolderivater som inhibitorer af fibrose |
| WO2015066456A1 (en) | 2013-10-31 | 2015-05-07 | Bristol-Myers Squibb Company | Radioligands for imaging the lpa-1 receptor |
| TR201909447T4 (tr) * | 2013-12-04 | 2019-07-22 | Galmed Res & Development Ltd | Aramkol tuzları. |
| GB201410741D0 (en) * | 2014-06-17 | 2014-07-30 | Babraham Inst And University Of Birmingham The | Novel diagnostic and therapeutic method |
| US10023554B2 (en) | 2014-06-27 | 2018-07-17 | Ube Industries, Ltd. | Halogen-substituted heterocyclic compound salt |
| CA2988306A1 (en) | 2015-06-05 | 2016-12-08 | Vertex Pharmaceuticals Incorporated | Triazoles for the treatment of demyelinating diseases |
| CA3005811A1 (en) * | 2015-11-20 | 2017-05-26 | Ube Industries, Ltd. | Pharmaceutical composition for treatment or prevention of nash |
| JP2018039755A (ja) * | 2016-09-08 | 2018-03-15 | 大塚化学株式会社 | ナトリウム２α−メチル−２β−（１，２，３−トリアゾール−１−イル）−メチルペナム−３α−カルボン酸１，１−ジオキシド一水和物結晶の製造方法 |
| JP2018039756A (ja) * | 2016-09-08 | 2018-03-15 | 大塚化学株式会社 | ナトリウム２α−メチル−２β−（１，２，３−トリアゾール−１−イル）−メチルペナム−３α−カルボン酸１，１−ジオキシド一水和物結晶の製造方法 |
| WO2018106643A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Heterocyclic azoles for the treatment of demyelinating diseases |
| WO2018106641A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Pyrazoles for the treatment of demyelinating diseases |
| WO2018106646A1 (en) | 2016-12-06 | 2018-06-14 | Vertex Pharmaceuticals Incorporated | Aminotriazoles for the treatment of demyelinating diseases |
| CN108318447B (zh) * | 2018-05-04 | 2020-12-18 | 山东大学 | 一种基于近红外光谱技术快速测定吡喹酮对映体组成的方法 |
| HRP20230243T1 (hr) | 2018-06-07 | 2023-04-14 | Idorsia Pharmaceuticals Ltd | Alkoksi supstituirani derivati piridinila kao antagonisti receptora lpa1 i njihova uporaba u liječenju fibroze |
| KR102224677B1 (ko) * | 2018-08-23 | 2021-03-08 | 가천대학교 산학협력단 | 티아졸로 피페라진 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물 |
| EP3853232B1 (en) * | 2018-09-18 | 2023-03-01 | Bristol-Myers Squibb Company | Oxabicyclo acids as lpa antagonists |
| US12209072B2 (en) | 2018-09-18 | 2025-01-28 | Bristol-Myers Squibb Company | Cyclopentyl acids as LPA antagonists |
| AR119162A1 (es) | 2019-06-18 | 2021-12-01 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-3-ilo |
| CN114728168B (zh) | 2019-11-15 | 2024-04-09 | 吉利德科学公司 | 三唑氨基甲酸酯吡啶基磺酰胺作为lpa受体拮抗剂及其用途 |
| CA3160410A1 (en) | 2019-12-04 | 2021-06-10 | Idorsia Pharmaceuticals Ltd | Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases |
| KR102393079B1 (ko) | 2020-02-28 | 2022-04-29 | 한국화학연구원 | 가축 호흡기 질환의 예방 또는 치료용 조성물 |
| CN111608208B (zh) * | 2020-05-19 | 2022-01-11 | 浙江鲁班建材科技股份有限公司 | 一种时间可控制的吸水膨胀堵漏型预铺卷材 |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| AU2021282986B2 (en) | 2020-06-03 | 2024-03-07 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
| US12383547B2 (en) | 2020-07-01 | 2025-08-12 | Vanderbilt University | Methods of treatment for a kidney disease |
| JP2022115835A (ja) * | 2021-01-28 | 2022-08-09 | 大正製薬株式会社 | Ｌｐａ１受容体を拮抗するウレア化合物の結晶形及びそれらの製造方法 |
| KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| AU2022405082B2 (en) | 2021-12-08 | 2025-09-25 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| KR102463504B1 (ko) | 2022-08-23 | 2022-11-04 | 주식회사 에네스지 | 원전 습분분리재열기의 종단온도차 보정 방법 |
| AU2024209233A1 (en) * | 2023-01-19 | 2025-07-31 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Pharmaceutically acceptable salt and crystal form of triazole compound, and preparation method therefor |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
| US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
| US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US6964975B2 (en) * | 2000-02-18 | 2005-11-15 | Kirin Beer Kabushiki Kaisha | Isoxazole and thiazole compounds and use thereof as medicine |
| WO2003055494A1 (en) | 2001-12-21 | 2003-07-10 | Avmax, Inc. | Use of ugt inhibitors to increase bioavailability |
| US20040014648A1 (en) | 2002-05-17 | 2004-01-22 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| AU2004240649A1 (en) | 2003-05-19 | 2004-12-02 | Irm, Llc | Immunosuppressant compounds and compositions |
| AR055041A1 (es) | 2005-03-23 | 2007-08-01 | Merck Frosst Canada Ltd | Tiadiazoles y oxadiazoles como inhibidores de la sintesis de leucotrienos. composiciones farmaceuticas. |
| AU2006279211A1 (en) | 2005-08-11 | 2007-02-15 | Merck Frosst Canada Ltd | Novel substituted 1,2,3-triazolylmethyl-benzothiophene or -indole and their use as leukotriene biosynthesis inhibitors |
| US7405302B2 (en) | 2005-10-11 | 2008-07-29 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US20070225285A1 (en) | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070219206A1 (en) | 2005-11-04 | 2007-09-20 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| WO2007087250A2 (en) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Tricyclic inhibitors of 5-lipoxygenase |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
-
2011
- 2011-12-07 ES ES11805292.7T patent/ES2674174T3/es active Active
- 2011-12-07 WO PCT/US2011/063817 patent/WO2012078805A1/en not_active Ceased
- 2011-12-07 PL PL11805292T patent/PL2648726T3/pl unknown
- 2011-12-07 JP JP2013543325A patent/JP6030567B2/ja not_active Expired - Fee Related
- 2011-12-07 CN CN201710849870.XA patent/CN107721940A/zh active Pending
- 2011-12-07 NO NO11805292A patent/NO2648726T3/no unknown
- 2011-12-07 SI SI201131465T patent/SI2648726T1/en unknown
- 2011-12-07 AU AU2011338417A patent/AU2011338417B2/en not_active Ceased
- 2011-12-07 SM SM20180320T patent/SMT201800320T1/it unknown
- 2011-12-07 RS RS20180740A patent/RS57377B1/sr unknown
- 2011-12-07 EP EP18163527.7A patent/EP3360552A1/en not_active Withdrawn
- 2011-12-07 HU HUE11805292A patent/HUE040397T2/hu unknown
- 2011-12-07 PT PT118052927T patent/PT2648726T/pt unknown
- 2011-12-07 KR KR1020137017670A patent/KR101875246B1/ko not_active Expired - Fee Related
- 2011-12-07 TR TR2018/09293T patent/TR201809293T4/tr unknown
- 2011-12-07 HR HRP20180970TT patent/HRP20180970T1/hr unknown
- 2011-12-07 BR BR112013013950A patent/BR112013013950A2/pt not_active IP Right Cessation
- 2011-12-07 DK DK11805292.7T patent/DK2648726T3/da active
- 2011-12-07 US US13/992,022 patent/US9556133B2/en active Active
- 2011-12-07 LT LTEP11805292.7T patent/LT2648726T/lt unknown
- 2011-12-07 SG SG2013043740A patent/SG191041A1/en unknown
- 2011-12-07 EP EP11805292.7A patent/EP2648726B1/en active Active
- 2011-12-07 MX MX2013006394A patent/MX347544B/es active IP Right Grant
- 2011-12-07 CA CA2820884A patent/CA2820884A1/en not_active Abandoned
- 2011-12-07 CN CN201180066933.5A patent/CN103596566B/zh not_active Expired - Fee Related
- 2011-12-07 EA EA201390840A patent/EA024967B1/ru not_active IP Right Cessation
-
2013
- 2013-06-02 IL IL226698A patent/IL226698B/en not_active IP Right Cessation
-
2016
- 2016-10-05 AU AU2016238848A patent/AU2016238848B2/en not_active Ceased
- 2016-12-16 US US15/381,562 patent/US20170121295A1/en not_active Abandoned
-
2018
- 2018-06-08 CY CY20181100603T patent/CY1120342T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2648726T3 (pl) | Policykliczny antagonista lpa1 i jego zastosowania | |
| NO2020015I1 (no) | drospirenone | |
| BR112012017441A2 (pt) | compostos e métodos | |
| ME03766B (me) | Određeni amino-pirimidini, njihove kompozicije, i metode njihove upotrebe | |
| DE112011100715T8 (de) | Hardware-hilfs-thread | |
| HRP20160737T1 (hr) | Anti-her3-protutijela i njihove uporabe | |
| PT2552242E (pt) | Resumo | |
| EP2609148A4 (en) | PHTHALIC ACID-FREE SOFT MAKER | |
| HRP20160922T1 (hr) | Oligopeptidni spojevi i njihove uporabe | |
| IL250606A0 (en) | D2 antagonists, methods of synthesis and methods of use | |
| EP2552212A4 (en) | IMPROVED FORMULATION | |
| BR112013002544A2 (pt) | seção de armario e armario | |
| EP2531023A4 (en) | IMPROVED FORMULATION | |
| HRP20150071T1 (xx) | Agomelatin hidroklorid hidrat i njegova priprava | |
| CO6781486A2 (es) | Compuestos y su uso | |
| DE112011101333A5 (de) | Parkouraufbau | |
| DK2468677T3 (da) | Stablekran | |
| DK2455322T3 (da) | Kran | |
| EP2647648A4 (en) | hydroxyalkylcellulose | |
| IT1398438B1 (it) | Dispositivo di premacinazione e relativo procedimento | |
| BR112012029669A2 (pt) | composição e método | |
| FR2964937B1 (fr) | Triporteur et direction de triporteur | |
| IT1399740B1 (it) | Cerniera bloccante | |
| IL229537A0 (en) | Hypertension and hyperuricemia | |
| DE11786796T8 (de) | Antigenpeptid und verwendung davon |